Drug Profile
Research programme: sepsis therapy - Ascentia Biomedical/University of Washington
Latest Information Update: 27 Mar 2008
Price :
$50
*
At a glance
- Originator University of Washington
- Developer Ascentia Biomedical Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sepsis
Most Recent Events
- 15 Aug 2005 Preclinical trials in Sepsis in USA (unspecified route)